The influence of different growth hormone addition protocols to poor ovarian responders on clinical outcomes in controlled ovary stimulation cycles: A systematic review and meta-analysis

Xue-Li Li, Li Wang, Fang Lv, Xia-Man Huang, Li-Ping Wang, Yu Pan, Xiao-Mei Zhang, Xue-Li Li, Li Wang, Fang Lv, Xia-Man Huang, Li-Ping Wang, Yu Pan, Xiao-Mei Zhang

Abstract

Background: Growth hormone (GH) is used as an adjuvant therapy in in vitro fertilization and embryo transfer (IVF-ET) for poor ovarian responders, but findings for its effects on outcomes of IVF have been conflicting. The aim of the study was to compare IVF-ET outcomes among women with poor ovarian responders, and find which subgroup can benefit from the GH addition.

Methods: We searched the databases, using the terms "growth hormone," "GH," "IVF," "in vitro fertilization." Randomized controlled trials (RCT) were included if they assessed pregnancy rate, live birth rate, collected oocytes, fertilization rate, and implantation rate. Extracted the data from the corresponding articles, Mantel-Haenszel random-effects model, or fixed-effects model was used. Eleven studies were included.

Results: Clinical pregnancy rate (RR 1.65, 95% CI 1.23-2.22), live birth rate (RR1.73, 1.25-2.40), collected oocytes number (SMD 1.09, 95% CI 0.54-1.64), MII oocytes number (SMD 1.48, 0.84-2.13), and E2 on human chorionic gonadotropin (HCG) day (SMD 1.03, 0.18-1.89) were significantly increased in the GH group. The cancelled cycles rate (RR 0.65, 0.45-0.94) and the dose of gonadotropin (Gn) (SMD -0.83, -1.47, -0.19) were significantly lower in patients who received GH. Subgroup analysis indicated that the GH addition with Gn significantly increased the clinical pregnancy rate (RR 1.76, 1.25-2.48) and the live birth rate (RR 1.91, 1.29-2.83).

Conclusion: The GH addition can significantly improve the clinical pregnancy rate and live birth rate. Furthermore, the GH addition time and collocation of medications may affect the pregnancy outcome.

Conflict of interest statement

Funding: This study was funded by the National Natural Science Foundation of China (Grant No. 81100421), National Natural Science Foundation of China (81601343), Top Six Talent Peaks Program of Jiangsu (2014-WSW-080), the National Science Foundation of Yangzhou (YZ2014050), and the National Science Foundation of Yangzhou (YZ2016110). All authors have no conflicts of interest.

The authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Flowchart of study selection.
Figure 2
Figure 2
Quality assessments of included studies. ? = unclear, + = low risk, – = high risk.
Figure 3
Figure 3
Forest plots for (A) clinical pregnancy rate, (B) live birth rate, (C) cancelled cycles rate, and (D) implantation rate. CI = confidence interval, GH = growth hormone.
Figure 4
Figure 4
Forest plots for (A) fertilization rate, (B) collected oocytes number, (C) metaphase II oocyte number, (D)E2 on HCG day, and (E) dose of gonadotropin. CI = confidence interval, GH = growth hormone.
Figure 5
Figure 5
Forest plots for subgroup analysis (A) GH addition with Gn subgroup, and (B) GH addition in the middle luteal phase subgroup. CI = confidence interval, GH = growth hormone, Gn = Gonadotropin.

References

    1. Keay SD, Liversedge NH, Mathur RS, et al. Assisted conception following poor ovarian response to gonadotrophin stimulation. Brit J Obstet Gynaecol 1997;104:521–7.
    1. Papathanasiou A, Searle BJ, King NMA, et al. Trends in ‘poor responder’ research: lessons learned from RCTs in assisted conception. Hum Reprod Update 2016;0:1–4.
    1. Sunkara SK, Tuthill J, Khairy M, et al. Pituitary suppression regimens in poor responders undergoing IVF treatment: a systematic review and meta-analysis. Reprod Biomed Online 2007;15:539–46.
    1. Surrey ES, Schoolcraft WB. Evaluating strategies for improving ovarian response of the poor responder undergoing assisted reproductive techniques. Fertil Steril 2000;73:667–76.
    1. Lashen H, Ledger W. Management of poor responders in IVF. Hum Reprod 1999;14:1919–21.
    1. Ferraretti AP, La Marca A, Fauser BCJM, et al. ESHRE consensus on the definition of ’poor response’ to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod 2011;26:1616–24.
    1. Ubaldi F, Rienzi L, Ferrero S, et al. Management of poor responders in IVF. Reprod Biomed Online 2005;10:235–46.
    1. Magon N, Agrawal S, Malik S, et al. Growth hormone in the management of female infertility. Indian J Endocrinol Metab 2011;15suppl 3:S246–7.
    1. Bachelot A, Monget P, Imbert-Bollore P, et al. Growth hormone is required for ovarian follicular growth. Endocrinology 2002;143:4104–12.
    1. Owen EJ, West C, Mason BA, et al. Co-treatment with growth hormone of sub-optimal responders in IVF-ET. Hum Reprod (Oxford, England) 1991;6:524–8.
    1. Kolibianakis EM, Venetis CA, Diedrich K, et al. Addition of growth hormone to gonadotrophins in ovarian stimulation of poor responders treated by in-vitro fertilization: a systematic review and meta-analysis. Hum Reprod Update 2009;15:613–22.
    1. Kyrou D, Kolibianakis EM, Venetis CA, et al. How to improve the probability of pregnancy in poor responders undergoing in vitro fertilization: a systematic review and meta-analysis. Fertil Steril 2009;91:749–66.
    1. Yu X, Ruan J, He LP, et al. Efficacy of growth hormone supplementation with gonadotrophins in vitro fertilization for poor ovarian responders: an updated meta-analysis. Int J Clin Exp Med 2015;8:4954–67.
    1. Harper K, Proctor M, Hughes E. Growth hormone for in vitro fertilization. Cochrane Database Syst Rev 2003;Cd000099.
    1. Bayoumi YA, Dakhly DR, Bassiouny YA, et al. Addition of growth hormone to themicroflare stimulation protocol among women with poor ovarian response. Int J Gynecol Obstet 2015;131:305–8.
    1. Zhuang GL, Wong SX, Zhou CQ. The effect of co-administration of low dosage growth hormone and gonadotropin for ovarian hyperstimulation in vitro fertilization and embryo transfer. Zhonghua Fu Chan Ke Za Zhi 1994;29:471–4. 510.
    1. Guan Q, Ma HG, Wang YY, et al. Effects of co-administration of growth hormone(GH) and aspirin to women during in vitro fertilization and embryo transfer (IVF-ET) cycles. Zhonghua Nan Ke Xue = Nat J Androl 2007;13:798–800.
    1. Liu D, Li Y, Wu L, et al. Influence of adjuvant growth hormone therapy on in-vitro fertilization and embryo transplantation in poor responders of superovulation. J Clin Res 2006;23:1219–24.
    1. Owen EJ, Shoham Z, Mason BA, et al. Cotreatment with growth hormone, after pituitary suppression, for ovarian stimulation in in vitro fertilization: a randomized, double-blind, placebo-control trial. Fertil Steril 1991;56:1104–10.
    1. Bassiouny YA, Dakhly DM, Bayoumi YA, et al. Does the addition of growth hormone to the in vitro fertilization/intracytoplasmic sperm injection antagonist protocol improve outcomes in poor responders? A randomized, controlled trial. Fertil Steril 2015;105:697–702.
    1. Kucuk T, Kozinoglu H, Kaba A. Growth hormone co-treatment within a GnRH agonist long protocol in patients with poor ovarian response: a prospective, randomized, clinical trial. J Assist Reprod Genet 2008;25:123–7.
    1. Suikkari A, MacLachlan V, Koistinen R, et al. Double-blind placebo controlled study: human biosynthetic growth hormone for assisted reproductive technology. Fertil Steril 1996;65:800–5.
    1. Bergh C, Hillensjo T, Wikland M, et al. Adjuvant growth hormone treatment during in vitro fertilization: a randomized, placebo-controlled study. Fertil Steril 1994;62:113–20.
    1. Eftekhar M, Aflatoonian A, Mohammadian F, et al. Adjuvant growth hormone therapy in antagonist protocol in poor responders undergoing assisted reproductive technology. Arch Gynecol Obstetr 2013;287:1017–21.
    1. Dor J, Seidman DS, Amudai E, et al. Adjuvant growth hormone therapy in poor responders to in-vitro fertilization: a prospective randomized placebo-controlled double-blind study. Hum Reprod (Oxford, England) 1995;10:40–3.
    1. Kiapekou E, Loutradis D, Drakakis P, et al. Effects of GH and IGF-I on the in vitro maturation of mouse oocytes. Hormones (Athens, Greece) 2005;4:155–60.
    1. Jeve YB, Bhandari HM. Effective treatment protocol for poor ovarian response: a systematic review and meta-analysis. J Hum Reprod Sci 2016;9:70–81.
    1. Dakhly DM, Bayoumi YA, Gad Allah SH. Which is the best IVF/ICSI protocol to be used in poor responders receiving growth hormone as an adjuvant treatment? A prospective randomized trial. Gynecol Endocrinol 2015;32:1–4.
    1. Lattes K, Brassesco M, Gomez M, et al. Low-dose growth hormone supplementation increases clinical pregnancy rate in poor responders undergoing in vitro fertilisation. Gynecol Endocrinol 2015;31:565–8.
    1. Hazout A, Junca A, Menezo Y, et al. Effect of growth hormone on oocyte competence in patients with multiple IVF failures. Reprod Biomed Online 2009;18:664–70.
    1. Yovich JL, Stanger JD. Growth hormone supplementation improves implantation and pregnancy productivity rates for poor-prognosis patients undertaking IVF. Reprod Biomed Online 2010;21:37–49.
    1. Rajesh H, Yong YY, Zhu M, et al. Growth hormone deficiency and supplementation at in-vitro fertilisation. Singapore Med J 2007;48:514–8.
    1. Schoolcraft W, Schlenker T, Gee M, et al. Improved controlled ovarian hyperstimulation in poor responder in vitro fertilization patients with a microdose follicle-stimulating hormone flare, growth hormone protocol. Fertil Steril 1997;67:93–7.
    1. Dunne C, Seethram K, Roberts J. Growth hormone supplementation in the luteal phase before microdose GnRH agonist flare protocol for in vitro dertilization. J Obstet Gynaecol Canada 2015;37:810–5.
    1. Gregoraszczuk EL, Bylica A, Gertler A. Response of porcine theca and granulosa cells to GH during short-term in vitro culture. Anim Reprod Sci 2000;58:113–25.
    1. Tapanainen J, Martikainen H, Voutilainen R, et al. Effect of growth hormone administration on human ovarian function and steroidogenic gene expression in granulosa-luteal cells. Fertil Steril 1992;58:726–32.
    1. de Ziegler D, Streuli I, Meldrum DR, et al. The value of growth hormone supplements in ART for poor ovarian responders. Fertil Steril 2011;96:1069–76.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit